welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals Awarded Key Patent on HEALER Technology
Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for two Thetis development candidates, TP-252 for familial adenomatous polyposis and TP-452 for dyslipidemia. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids. National filings outside of the United States are underway.
expertly curated content related to this topic
-
The Genetic Basis of Familial Adenomatous Polyposis and its Implications for Clinical Practice and Risk ManagementAmongst other F.A.P.-centric things, thi...
-
In a Select Group of Patients Meeting Strict Clinical Criteria and Undergoing Ileal Pouch-Anal Anastomosis, the Omis...PURPOSE : Ileal pouch-anal anastomosis i...
-
Erica B. Sneider, MDSpecialization: Colon & Rectal Surg...
-
Preventive Effects of Low-Dose Aspirin on Colorectal Adenoma Growth in Patients with Familial Adenomatous Polyposis:...There are several reports of clinical tr...
-
Meagan Costedio, MDMeagan Costedio, MD, is a Staff Member i...
-
Invisible: How Young Women with Serious Health Issues Navigate Work, Relationships, and the Pressure to Seem Just Fi...Already appearing on must-read lists for...